# Aspirin to Target Arterial Events in Chronic Kidney Disease

Study · id `cardio:ct-nct03796156` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03796156](<https://clinicaltrials.gov/study/NCT03796156>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03796156

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 4633 participants.

## Technical summary

Registry record NCT03796156. Randomized; single masking; primary purpose prevention. Start 2019-02-25 (actual); primary completion 2024-09-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 4633 participants (enrolled count; ClinicalTrials.gov record NCT03796156, source copy `cardio:ctgov-nct03796156-2026-03-20`, retrieved 2026-10-26)
- Started: 2019-02-25 (actual) (ClinicalTrials.gov record NCT03796156, source copy `cardio:ctgov-nct03796156-2026-03-20`, retrieved 2026-10-26)
- Primary completion: 2024-09-30 (actual) (ClinicalTrials.gov record NCT03796156, source copy `cardio:ctgov-nct03796156-2026-03-20`, retrieved 2026-10-26)
- Completion: 2025-09-23 (actual) (ClinicalTrials.gov record NCT03796156, source copy `cardio:ctgov-nct03796156-2026-03-20`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT03796156, source copy `cardio:ctgov-nct03796156-2026-03-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03796156-2026-03-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Aspirin to Target Arterial Events in Chronic Kidney Disease
- Acronym: ATTACK
- Condition: Chronic Kidney Diseases
- Condition: Cardiovascular Diseases
- Condition: Bleeding
- Intervention (Drug): Aspirin
- Lead sponsor: University of Southampton
- Lead sponsor class: OTHER
- Collaborator: University of Nottingham
- Collaborator class: OTHER
- Collaborator: University of Warwick
- Collaborator class: OTHER
- Collaborator: Nottingham University Hospitals NHS Trust
- Collaborator class: OTHER
- Collaborator: East Kent Hospitals University NHS Foundation Trust
- Collaborator class: OTHER\_GOV
- Collaborator: University of Durham
- Collaborator class: OTHER
- Collaborator: Epsom and St Helier University Hospitals NHS Trust
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as a collaborator: University of Warwick (`cardio:org-university-of-warwick`)

## Provenance

Content hash: 1e97bd8017ba9da80ac4a1783c465939fb2584f2958cbf729579f7157f3170fa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
